Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AIM Vaccine Co. inactivated COVID-19 vaccine
- Development stage
- Preclinical
- Lead developer
- AIM Vaccine Co.
- Modality
- Whole Inactivated Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
The AIM Vaccine Co. inactivated COVID-19 vaccine is an investigational whole-virus vaccine candidate developed for the prevention of COVID-19. Utilizing AIM Vaccine Co.'s viral vaccine platform, the candidate is produced by cultivating the SARS-CoV-2 virus in cell culture and subsequently inactivating it to ensure it cannot replicate while maintaining its antigenic properties. This approach is designed to present the full array of viral proteins, including the spike, envelope, membrane, and nucleocapsid proteins, to the host immune system to elicit a broad humoral immune response and the production of neutralizing antibodies. The vaccine is currently in the preclinical research stage of development.
- Other names
- Inactivated SARS-CoV-2 vaccineInactivated COVID-19 vaccine
Beyond the preview
Go deeper on AIM Vaccine Co. inactivated COVID-19 vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AIM Vaccine Co. inactivated COVID-19 vaccine.